# Pediatric Malignancies Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $183,261

## Abstract

Pediatric Malignancies Program: Summary/Abstract
Pediatric malignancies encompass a range of tumor types, and HDFCCC Pediatric Malignancy (PE) Program
members are focused on diverse cancers, including leukemias, brain tumors, and sarcoma. Many of these are
embryonal tumors, cancers that begin in embryonic tissues and that often represent failure of normal
differentiation. The goal of the PE Program is to advance the development of new therapies for pediatric
cancer by enabling basic, translational, and clinical research with the goal of developing new effective targeted
therapies for children with minimal toxicities. Specifically, PE member research focuses on (1) discovering and
validating novel therapeutic targets for pediatric cancers; (2) clinically advancing new therapeutic strategies to
improve outcomes for pediatric cancer patients; and (3) understanding the link between cancer and normal
human development.

## Key facts

- **NIH application ID:** 10932211
- **Project number:** 5P30CA082103-25
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Eric Alejandro Sweet-Cordero
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $183,261
- **Award type:** 5
- **Project period:** 1999-08-05 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10932211

## Citation

> US National Institutes of Health, RePORTER application 10932211, Pediatric Malignancies Program (5P30CA082103-25). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10932211. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*